ERBB2 and breast carcinoma: The magnitude of TILs varies along breast cancer subtypes, with TNBC and HER2 + exhibiting a higher CD8 + T cell infiltration than luminal type cases explaining, at least partly, the improved response of TNBC to immunotherapy [6].